The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management. • Bone-targeted agents significantly reduce skeletal morbidity in patients with bone metastases across tumour types and should be part of standard treatment. • Treatment-induced bone loss increases fracture risk and may require use of a bone-targeted agent in addition to lifestyle modifications. • The addition of a bisphosphonate to standard adjuvant therapies for postmenopausal early breast cancer reduces bone recurrence and improves survival.
Bone health in cancer. ESMO Clinical Practice Guidelines / Coleman, R; Hadji, P; Body, Jj; Santini, D; Chow, E; Terpos, E; Oudard, S; Bruland, O; Flamen, P; Kurth, A; Van Poznak, C; Aapro, M; Jordan, K. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 31:12(2020), pp. 1650-1663. [10.1016/j.annonc.2020.07.019]
Bone health in cancer. ESMO Clinical Practice Guidelines
Santini D;
2020
Abstract
The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management. • Bone-targeted agents significantly reduce skeletal morbidity in patients with bone metastases across tumour types and should be part of standard treatment. • Treatment-induced bone loss increases fracture risk and may require use of a bone-targeted agent in addition to lifestyle modifications. • The addition of a bisphosphonate to standard adjuvant therapies for postmenopausal early breast cancer reduces bone recurrence and improves survival.| File | Dimensione | Formato | |
|---|---|---|---|
|
Coleman_Bone_2020.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
514.8 kB
Formato
Adobe PDF
|
514.8 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
